The Quantellect read.As of Nov 19, 2026, 5 active firms cover Alpha Tau Medical Ltd: 4 rate it Buy or better, 1 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. The target range is very wide, $8.00 to $30.00 (about 3.8x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $15.40 sits 28% above the current $12.04. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.16 next quarter toward $-0.54 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS5 active firms
Buy
Strong Buy00%
Buy480%
Neutral120%
Sell00%
Strong Sell00%
Based on 5 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$15.40
+28.0% upside
Average target across 5 active firms as of Nov 19, 2026 vs $12.04 current
Highest Target$30.00
Average Target$15.40
Lowest Target$8.00
Detailed analyst forecasts for DRTS
Showing 1–5 of 5 named analysts shown · 5 active firms in the rating projection
As of Nov 19, 2026, 4 of 5 active firms rate DRTS a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
DRTS EPS & revenue forecast
EPS · NEXT QUARTER
$-0.16
Range $-0.17 – $-0.15 · 4 analysts · +12% YoY
Next period, 4 analysts expect Alpha Tau Medical Ltd to earn $-0.16 a share (range $-0.17 – $-0.15), versus $-0.14 a year earlier. Full-year consensus is $-0.96, growing to $-0.54 the year after.
REVENUE · NEXT QUARTER
$333.3K
Range $0 – $1.0M · 4 analysts
Revenue is expected to reach $333.3K (range $0 – $1.0M). Full-year consensus is $503.3K, rising to $10.7M next year.
Top analysts covering Alpha Tau Medical Ltd
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on DRTS.
#1
Yi Chen
HC Wainwright & Co. · Rank #350
Buy
$16.00+32.9% to target
Overall win rate
34%
+ Follow
#2
Jason Bednar
Piper Sandler · Rank #360
Neutral
$8.00-33.5% to target
Overall win rate
33%
+ Follow
#3
Yigal Nochomovitz
Citigroup · Rank #381
Buy
$9.00-25.2% to target
Overall win rate
38%
+ Follow
#4
LS
Lukas Shumway
Barclays
Buy
$30.00+149.3% to target
Coverage
—
+ Follow
#5
JC
Jeff Cohen
Ladenburg Thalmann
Buy
$14.00+16.3% to target
Coverage
—
+ Follow
DRTS stock forecast FAQ
What is DRTS's average 12-month price target?+
The 5 active firms with a live target average $15.40 for Alpha Tau Medical Ltd over the next 12 months, ranging from a $30.00 high to a $8.00 low, as of Nov 19, 2026.
Is DRTS stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 5 active firms as of Nov 19, 2026, 4 rate it Buy or Strong Buy, 1 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for DRTS?+
The Street-high target is $30.00 (Barclays), and the Street-low is $8.00 (Piper Sandler). The average of all 5 active-firm targets is $15.40.
How many active Wall Street firms cover DRTS?+
5 active firms have a recognized rating on Alpha Tau Medical Ltd as of Nov 19, 2026, and 5 active firms carry a live 12-month price target.
Who is the most accurate analyst covering DRTS?+
Among analysts who currently cover DRTS, Yi Chen of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #350). Their current call is Buy with a $16.00 target.
What is Alpha Tau Medical Ltd's projected EPS for next quarter?+
The consensus estimate is $-0.16 per share (range $-0.17 – $-0.15) across 4 analysts. Full-year EPS is projected at $-0.96, rising to $-0.54 the following year.
How much revenue is Alpha Tau Medical Ltd expected to report next quarter?+
Consensus revenue is $333.3K (range $0 – $1.0M). Full-year revenue is projected at $503.3K, growing to $10.7M next year.
Have analysts been upgrading or downgrading DRTS lately?+
As of Nov 19, 2026, 4 of 5 active firms rate DRTS a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their DRTS calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.